Form 8-K for MULTICELL TECHNOLOGIES, INC.
--------------------------------------------------------------------------------
19-Mar-2009
Entry into a Material Definitive Agreement, Other Events
Item 1.01 Entry Into a Material Definitive Agreement.
On March 17 2009, MultiCell Technologies, Inc. ("MultiCell") executed Cooperative Research and Product Development Agreement (the "Agreement") with Maxim Biotech, Inc. ("Maxim") of Rockville, MD. Under the terms of the Agreement, Maxim and MultiCell will jointly research and develop products related to the isolation, characterization, differentiation and function of human hepatocyte cells and human liver stem cells.
MultiCell and Maxim plan to develop, manufacture and market a family of reagents and reagent tool kits sold under MultiCell's brand name which target life science research ("LSR") application with a particular focus on products used for liver stem-related LSR applications.
Item 8.01 Other Events
On March 19, 2009, MultiCell issued a press release announcing the execution of the Agreement. A copy of this press release is attached hereto as Exhibit
99.1. This summary is qualified in its entirety by reference to Exhibit 99.1 to this current report. The press release and the information therein are being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Exhibits
Exhibit No. Description
10.1* Cooperative Research and Product Development Agreement between
MultiCell Technologies, Inc. and Maxim Biotech, Inc. dated March 17,
2009.
99.1 Press Release dated March 19, 2009.
* Confidential treatment has been requested with respect to certain portions of this exhibit pursuant to a request for confidential treatment under Rule 24b-2 promulgated under the Exchange Act. Omitted portions have been filed separately with the Securities and Exchange Commission.
biz.yahoo.com |
